Pipeline
Aldeyra Is a Well-Capitalized Biotechonology Company with a Broad Immunology Pipeline
| Product Candidates | Disease Targets | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
|---|---|---|---|---|---|---|
ReproxalapDisease Targets: Dry Eye Disease Type (ophthalmic solution) | Dry Eye Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ReproxalapDisease Targets: Allergic Conjunctivitis Type (ophthalmic solution) | Allergic Conjunctivitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Atopic Dermatitis (Part 1) Type (oral administration) | Atopic Dermatitis (Part 1) | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Chronic Cough Type (oral administration) | Chronic Cough | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Idiopathic Nephrotic Syndrome (Part 1) Type (oral administration) | Idiopathic Nephrotic Syndrome (Part 1) | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Sjögren-Larsson Syndrome Type (oral administration) | Sjögren-Larsson Syndrome | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-629Disease Targets: Moderate Alcoholic Hepatitis Type (oral administration) | Moderate Alcoholic Hepatitis | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-246Disease Targets: Systemic Immune-Mediated Diseases Type (oral administration) | Systemic Immune-Mediated Diseases | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-248Disease Targets: Geographic Atrophy Type (intravitreal injection) | Geographic Atrophy | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-2191(U.S FDA Orphan Drug and Fast Track DesignationDisease Targets: Proliferative Vitreoretinopathy Type (intravitreal injection) | Proliferative Vitreoretinopathy | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |
ADX-2191U.S. FDA Orphan-Drug DesignationDisease Targets: Retinitis Pigmentosa Type (intravitreal injection) | Retinitis Pigmentosa | Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Review |